Accessibility Menu
Diagnos logo

Diagnos(OTC) DGNOF

Market Cap$40.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-72%
5 Year-15%
1 Year+75%
1 Month+54%
$0.34
+0.47%
+0.00Today
Diagnos last closing stock price
MetricPriceDate
Last closeUSD 0.342026-09-04
Diagnos stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.98%USD 0.362026-08-28
1 month+54.38%USD 0.222026-08-05
3 month+117.75%USD 0.162026-06-05
Year to date+27.84%USD 0.262025-12-31
1 year+74.7%USD 0.192025-09-04
3 year-8.54%USD 0.372023-08-30
5 year-15.38%USD 0.402021-09-03
Since inception-72.49%USD 1.232012-07-30

Diagnos Financials at a Glance

Market Cap

$40.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$65.50K

Net Income (TTM)

-CA$4.56M

EPS (TTM)

-$0.03

P/E Ratio

-11.32

Dividend

$0.00

Beta (Volatility)

0.28 (Low)

Price

$0.34

Volume

24,000

Open

$0.34

Previous Close

$0.34

Daily Range

$0.34 - $0.34

52-Week Range

$0.13 - $0.36

Estimated Earnings Date

Sep 8, 2026

DGNOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Diagnos

DIAGNOS Inc. specializes in technology-driven services primarily in the healthcare sector. The company is known for its innovative Computer Assisted Retina Analysis (CARA) software, which aids in the detection of diabetic retinopathy.

Products and Services
  • Computer Assisted Retina Analysis (CARA) software for eye care professionals
  • Consulting services in data analytics and artificial intelligence
  • Healthcare technology solutions across multiple countries
Growth Outlook
  • Expansion into international markets, including Colombia and Saudi Arabia
  • Increasing demand for telemedicine and digital health solutions
  • Focus on enhancing CARA software capabilities to improve diagnostic accuracy
Financial Highlights
  • Recent quarterly revenue of CAD 15,750, showing consistent performance
  • Trailing twelve months (TTM) net income margin of -69.57%, indicating potential for improvement
  • Current ratio of 1.49, suggesting adequate short-term financial health
DIAGNOS Inc. has established itself as a key player in the healthcare technology sector, particularly with its CARA software, which is designed to assist medical professionals in diagnosing eye diseases. The company operates in various countries, enhancing its market reach and potential for growth. Recent financial data indicates a revenue of CAD 15,750 for the latest quarter, reflecting a stable performance amidst ongoing challenges. The TTM net income margin of -69.57% highlights areas for operational improvement, while a current ratio of 1.49 suggests that the company is well-positioned to meet its short-term obligations. As the demand for digital health solutions continues to rise, DIAGNOS Inc. is poised to capitalize on emerging opportunities in the healthcare landscape.
AI Generated • Sep 3, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

André M. Larente

Website

www.diagnos.com

Headquarters

Brossard, QC J4Z 1A7, CA

DGNOF Financials

Key Financial Metrics (TTM)

Gross Margin

-182.42%

Operating Margin

-6510.52%

Net Income Margin

-6956.84%

Return on Equity

11659.44%

Return on Capital

-204.11%

Return on Assets

-190.55%

Earnings Yield

-8.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$40.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

120.41M

Volume

24.00K

Avg. Volume

100.91K

Financials (TTM)

Gross Profit

-CA$1.49M

Operating Income

-CA$4.23M

EBITDA

-CA$4.06M

Operating Cash Flow

-CA$3.86M

Capital Expenditure

-CA$11.07K

Free Cash Flow

-CA$3.87M

Cash & ST Invst.

CA$1.93M

Total Debt

CA$1.41M

Diagnos Performance Analysis

Diagnos annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31CAD 367,1894.9%
20242024-03-31CAD 126,152-65.6%
20252025-03-31CAD 74,624-40.8%
20262026-03-31CAD 47,376-36.5%
Diagnos sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-305.5%
Q22025-09-30-21.9%
Q32025-12-310.2%
Q42026-03-313.7%
Diagnos annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31CAD -0.03-11.2%
20242024-03-31CAD -0.0318.2%
20252025-03-31CAD -0.039.7%
20262026-03-31CAD -0.03-12.6%
Diagnos sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-06-3019.3%
Q22025-09-301.8%
Q32025-12-317.5%
Q42026-03-311.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

CA$15.75K

-14.4%

Gross Profit

-CA$352.82K

-21.5%

Gross Margin

-22.40%

N/A

Market Cap

$40.75MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.85M

N/A

Employees

22

N/A

Net Income

-CA$1.19M

+11.2%

EBITDA

-CA$1.12M

+3.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

CA$1.93M

-40.3%

Total Debt

CA$1.41M

-54.3%

Accounts Receivable

CA$212.93K

+39.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$226.29K

-20.9%

Short Term Debt

CA$1.18M

-57.8%

Return on Assets

-1.91%

N/A

Return on Invested Capital

-4.67%

N/A

Free Cash Flow

-CA$1.32M

-6.0%

Operating Cash Flow

-CA$1.32M

-6.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBIXFBonus Biogroup Ltd.
$0.04+33.33%
POSCPositron Corporation
$1.80-0.77%
CRVWCareView Communications, Inc.
$0.04+0.00%
IPDQFImpediMed Limited
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$102.89+0.07%
NVDANvidia
$227.68-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.65+0.05%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$43.78-0.06%

Questions About DGNOF

What is the current price of Diagnos?

Diagnos is trading at $0.34 per share.

What is the 52-week range for Diagnos?

Over the past 52 weeks, Diagnos has traded between $0.13 and $0.36.

How much debt does Diagnos have?

As of the most recent reporting period, Diagnos reported total debt of CA$1.00M.

How much cash does Diagnos have on hand?

Diagnos reported CA$222.14K in cash and cash equivalents in its most recent financial results.

What is Diagnos’s dividend yield?

Diagnos does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services